Pfizer: Prevnar 13 immunogenic in children, adolescents

Pfizer Inc. (NYSE:PFE) said Prevnar 13 met all study endpoints in a Phase III trial to prevent pneumococcal disease in healthy children aged 5-17 years old. The pharma said the pneumococcal vaccine demonstrated immunogenicity at one month post-vaccination regardless of prior vaccination with Prevnar ( PCV7), the pharma's vaccine containing seven serotypes. The open-label trial enrolled 598 children in two groups: healthy children aged 5-10 years of age previously vaccinated with at least one dose of PCV7; and healthy pneumococcal vaccine-naive children aged 10-18 years of age. Data were presented at the International Symposium on Pneumococci and Pneumococcal Diseases in Iguazu Falls. ...